Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.17%
1,106.36
-1.87
-0.17%
—1,108.231,109.651,115.881,105.59——
SIXC
Communications
SIXC
Communications
SIXC
+0.77%
610.29
+4.66
+0.77%
—605.63605.63611.69602.96——
SIXE
Energy
SIXE
Energy
SIXE
+0.10%
1,211.22
+1.27
+0.10%
—1,209.951,210.981,212.701,197.20——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.43%
1,750.71
-7.52
-0.43%
—1,758.231,759.031,760.641,739.69——
SIXM
Financials
SIXM
Financials
SIXM
-1.07%
628.17
-6.77
-1.07%
—634.94632.49632.49627.63——
SIXR
Staples
SIXR
Staples
SIXR
+0.26%
854.57
+2.20
+0.26%
—852.37850.81859.97849.13——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.90%
216.87
-1.98
-0.90%
—218.85218.85218.85215.61——
SIXT
Technology
SIXT
Technology
SIXT
+0.95%
3,561.94
+33.45
+0.95%
—3,528.493,565.203,578.773,509.18——
SIXU
Utilities
SIXU
Utilities
SIXU
-1.26%
903.31
-11.51
-1.26%
—914.82910.36910.36897.78——
SIXV
Health care
SIXV
Health care
SIXV
+0.63%
1,481.54
+9.27
+0.63%
—1,472.271,470.891,484.151,466.47——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.39%
2,399.95
+9.34
+0.39%
—2,390.612,387.312,409.702,373.97——
MRNA:NASDAQ
Moderna Inc
$50.42
0.00%
(0.00) 1D
$49.50
-1.82% (-0.92)
Pre-market
Closed: May 13, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MRNA...
Mkt. cap
20.01B
Avg. vol.
7.23M
Volume
104.73K
52-wk high
$59.55
52-wk low
$22.29
EPS
-$8.15
Beta
1.05
Shares outstanding
396.79M
No. of employees
5K
News stories
From sources across the web
Profile
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines. Wikipedia
About Moderna Inc
CEOStéphane Bancel
Employees4.7K
FoundedSep 2010
Headquarters-
SectorBiotechnology
Websitemodernatx.com
Last report
May 1, 2026
Fiscal Period
Q1 2026
EPS / Est. (USD)
-$1.18 / -$3.96
+70.18%beat
Revenue / Est. (USD)
389.00M / 236.36M
+64.58%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
142.00M
1.02B
678.00M
389.00M
Cost of goods sold
819.00M
1.01B
1.23B
726.00M
Cost of revenue
819.00M
1.01B
1.23B
726.00M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
230.00M
268.00M
308.00M
173.00M
Operating expense
230.00M
268.00M
308.00M
173.00M
Total operating expenses
1.05B
1.28B
1.54B
899.00M
Operating income
-907.00M
-260.00M
-857.00M
-510.00M
Other non operating income
9.00M
-4.00M
-2.00M
-
EBT including unusual items
-818.00M
-187.00M
-799.00M
-1.33B
EBT excluding unusual items
-818.00M
-191.00M
-797.00M
-455.00M
Income tax expense
7.00M
13.00M
27.00M
9.00M
Effective tax rate
-0.86%
-6.95%
-3.38%
-0.67%
Other operating expenses
-
-
-
-
Net income
-825.00M
-200.00M
-826.00M
-1.34B
Net profit margin
-580.99%
-19.68%
-121.83%
-345.24%
Earnings per share
-2.13
-0.51
-2.11
-1.18
Interest and investment income
81.00M
73.00M
70.00M
72.00M
Interest expense
-1.00M
-
-8.00M
-17.00M
Net interest expenses
80.00M
73.00M
62.00M
55.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
-850.00M
-208.00M
-790.00M
-451.00M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer